Role of glucocorticoids in breast cancer

Current Pharmaceutical Design

Volumn 16, Issue 32, 2010, Pages 3593-3600

  Vaidya, Jayant S ^a   Baldassarre, Gustavo ^b   Thorat, Mangesh A ^c   Massarut, Samuele ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Breast cancer; Circadian; Glucocorticoid receptor; Glucocorticoids; Paracrine; Review; Steroids; Treatment

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANTIESTROGEN; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ESTROGEN RECEPTOR; EXEMESTANE; FLUOROURACIL; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR ALPHA; GLUCOCORTICOID RECEPTOR BETA; LETROZOLE; METHOTREXATE; MIFEPRISTONE; MITOXANTRONE; PACLITAXEL; PREDNISONE; TAMOXIFEN; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CELL PROLIFERATION; CHEMOSENSITIVITY; CIRCADIAN RHYTHM; DRUG PROTEIN BINDING; FEEDBACK SYSTEM; HUMAN; LEUKOPENIA; MENSTRUAL CYCLE; METASTASIS; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOCYTOPENIA;

BREAST NEOPLASMS; CIRCADIAN RHYTHM; FEMALE; GLUCOCORTICOIDS; HUMANS;

EID: 78650905197     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210793797906     Document Type: Article

References (116)

1. Franchimont D. Overview of the actions of glucocorticoids on theimmune response: a good model to characterize new pathways ofimmunosuppression for new treatment strategies. Ann N Y Acad Sci 2004; 1024: 124-37.
2. Kerppola TK, Luk D, Curran T. Fos is a preferential target of glu-cocorticoid receptor inhibition of AP-1 activity in vitro. Mol Cell Biol 1993; 13: 3782-91.
3. Jonat C, Rahmsdorf HJ, Park KK, et al. Antitumor promotion andantiinflammation: down-modulation of AP-1 (Fos/Jun) activity byglucocorticoid hormone. Cell 1990; 62: 1189-204.
4. Wyszomierski SL, Yeh J, Rosen JM. Glucocorticoid recep-tor/signal transducer and activator of transcription 5 (STAT5) in-teractions enhance STAT5 activation by prolonging STAT5 DNAbinding and tyrosine phosphorylation. Mol Endocrinol 1999; 13:330-43.
5. McKay LI, Cidlowski JA. Cross-talk between nuclear factor-kappaB and the steroid hormone receptors: mechanisms of mutual an-tagonism. Mol Endocrinol 1998; 12: 45-56.
6. Brostjan C, Anrather J, Csizmadia V, et al. Glucocorticoid-mediated repression of NFkappaB activity in endothelial cells doesnot involve induction of IkappaBalpha synthesis. J Biol Chem 1996; 271: 19612-19616.
7. Conzen SD. Minireview: nuclear receptors and breast cancer. Mol Endocrinol 2008; 22: 2215-28.
8. Duma D, Jewell CM, Cidlowski JA. Multiple glucocorticoid recep-tor isoforms and mechanisms of post-translational modification. J Steroid Biochem Mol Biol 2006; 102: 11-21.
9. Joëls M, Karst H, DeRijk R, de Kloet ER. The coming out of thebrain mineralocorticoid receptor. Trends Neurosci 2008; 31: 1-7.
10. Marques, AH, Silverman, MN, Sternberg, EM. Glucocorticoiddysregulations and their clinical correlates. From receptors totherapeutics. Ann NY Acad Sci 2009; 1179: 1-18.
11. Segnitz B, Gehring U. Subunit structure of the nonactivated humanestrogen receptor. Proc Natl Acad Sci USA 1995; 92: 2179-83.
12. Zhang S, Liang X, Danielsen M. Role of the C terminus of theglucocorticoid receptor in hormone binding and agonist/antagonistdiscrimination. Mol Endocrinol 1996; 10: 24-34.
13. Kinyamu HK, Archer TK. Estrogen receptor-dependent proteaso-mal degradation of the glucocorticoid receptor is coupled to an in-crease in mdm2 protein expression. Mol Cell Biol 2003; 23: 5867-81.
14. Zhang Y, Leung DY, Nordeen SK, Goleva E. Estrogen inhibitsglucocorticoid action via protein phosphatase 5 (PP5)-mediatedglucocorticoid receptor dephosphorylation. J Biol Chem 2009; 284:24542-52.
15. Gong H, Jarzynka MJ, Cole TJ, et al. Glucocorticoids antagonizeestrogens by glucocorticoid receptor-mediated activation of estro-gen sulfotransferase. Cancer Res 2008; 68: 7386-93.
16. van den Akker ELT, Koper JW, van Rossum EFC, et al. Glucocor-ticoid receptor gene and risk of cardiovascular disease. Arch InternMed 2008; 168: 33-9.
17. van Rossum EFC, Russcher H, Lamberts SWJ. Genetic polymor-phisms and multifactorial diseases: facts and fallacies revealed bythe glucocorticoid receptor gene. Trends Endocrinol Metabol 2005;16: 445-50.
18. Pisani P. Hyper-insulinaemia and cancer, meta-analyses of epide-miological studies. Arch Physiol Biochem 2008; 114: 63-70.
19. Key TJ, Appleby PN, Reeves GK, Roddam AW. Insulin-likegrowth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), andbreast cancer risk: pooled individual data analysis of 17 prospectivestudies. Lancet Oncol 2010; 11: 530-42.
20. Sorensen HT, Mellemkjaer L, Skriver MV, et al. NO excess risk ofbreast cancer among female users of systemic glucocorticoids.Cancer Epidemiol Biomarkers Prev 2005; 14: 1022-3.
21. Parikh-Patel A, White RH, Allen M, Cress R. Risk of canceramong rheumatoid arthritis patients in California. Cancer CausesControl 2009; 20: 1001-10.
22. Gadalla SM, Amr S, Langenberg P, et al. Breast cancer risk inelderly women with systemic autoimmune rheumatic diseases: apopulation-based case-control study. Br J Cancer 2009; 100: 817-21.
23. Smitten AL, Simon TA, Hochberg MC, Suissa S. A meta-analysisof the incidence of malignancy in adult patients with rheumatoidarthritis. Arthritis Res Ther 2008; 10: R45.
24. Amsterdam A, Sasson R. The anti-inflammatory action of gluco-corticoids is mediated by cell type specific regulation of apoptosis. Mol Cell Endocrinol 2002; 189: 1-9.
25. Messmer UK, Pereda-Fernandez C, Manderscheid M, Pfeilschifter J. Dexamethasone inhibits TNF-alpha-induced apoptosis and IAPprotein downregulation in MCF-7 cells. Br J Pharmacol 2001; 133:467-76.
26. Buchmann A, Willy C, Buenemann CL, et al. Inhibition of trans-forming growth factor beta1-induced hepatoma cell apoptosis byliver tumor promoters: characterization of primary signaling eventsand effects on CPP32-like caspase activity. Cell Death Differ 1999;6: 190-200.
27. Yamamoto M, Fukuda K, Miura N, et al. Inhibition by dexametha-sone of transforming growth factor beta1-induced apoptosis in rathepatoma cells: a possible association with Bcl-xL induction. He-patology 1998; 27: 959-66.
28. Hammer S, Sauer B, Spika I, et al. Glucocorticoids mediate differ-ential anti-apoptotic effects in human fibroblasts and keratinocytesvia sphingosine-1-phosphate formation. J Cell Biochem 2004; 91:840-51.
29. Gascoyne DM, Kypta RM, Vivanco MM. Glucocorticoids inhibitapoptosis during fibrosarcoma development by transcriptionally ac-tivating Bcl-xL. J Biol Chem 2003; 278: 18022-9.
30. Baumann S, Dostert A, Novac N, et al. Glucocorticoids inhibitactivation-induced cell death (AICD) via direct DNA-dependentrepression of the CD95 ligand gene by a glucocorticoid receptordimer. Blood 2005; 106: 617-25.
31. Yang Y, Fang S, Jensen JP, Weissman AM, Ashwell JD. Ubiquitinprotein ligase activity of IAPs and their degradation in proteasomesin response to apoptotic stimuli. Science 2000; 288: 874-7.
32. Herr I, Pfitzenmaier J. Glucocorticoid use in prostate cancer andother solid tumours: implications for effectiveness of cytotoxictreatment and metastases. Lancet Oncol 2006; 7: 425-30.
33. Mikosz CA, Brickley DR, Sharkey MS, Moran TW, Conzen SD.Glucocorticoid receptor-mediated protection from apoptosis is as-sociated with induction of the serine/threonine survival kinasegene, sgk-1. J Biol Chem 2001; 276: 16649-54.
34. Pang D, Kocherginsky M, Krausz T, Kim SY, Conzen SD. Dex-amethasone decreases xenograft response to Paclitaxel through in-hibition of tumor cell apoptosis. Cancer Biol Ther 2006; 5: 933-40.
35. Sui M, Chen F, Chen Z, Fan W. Glucocorticoids interfere withtherapeutic efficacy of paclitaxel against human breast and ovarianxenograft tumors. Int J Cancer 2006; 119: 712-7.
36. Wu W, Chaudhuri S, Brickley DR, et al. Microarray analysis re-veals glucocorticoid-regulated survival genes that are associatedwith inhibition of apoptosis in breast epithelial cells. Cancer Res 2004; 64: 1757-64.
37. Zhang C, Beckermann B, Kallifatidis G, et al. Corticosteroidsinduce chemotherapy resistance in the majority of tumour cellsfrom bone, brain, breast, cervix, melanoma and neuroblastoma. IntJ Oncol 2006; 29: 1295-301.
38. Gorman AM, Hirt UA, Orrenius S, Ceccatelli S. Dexamethasonepre-treatment interferes with apoptotic death in glioma cells. Neu-roscience 2000; 96: 417-25.
39. Rieger J, Durka S, Streffer J, Dichgans J, Weller M. Gemcitabinecytotoxicity of human malignant glioma cells: modulation by anti-oxidants, BCL-2 and dexamethasone. Eur J Pharmacol 1999; 365:301-8.
40. Wolff JE, Denecke J, Jurgens H. Dexamethasone induces partialresistance to cisplatinum in C6 glioma cells. Anticancer Res 1996;16: 805-9.
41. Benedetti S, Pirola B, Poliani PL, et al. Dexamethasone inhibits theanti-tumor effect of interleukin 4 on rat experimental gliomas. Gene Ther 2003; 10: 188-92.
42. Wolff JE, Jurgens H. Dexamethasone induced partial resistance tomethotrexate in C6-glioma cells. Anticancer Res 1994; 14: 1585-8.
43. Herr I, Ucur E, Herzer K, et al. Glucocorticoid cotreatment inducesapoptosis resistance toward cancer therapy in carcinomas. CancerRes 2003; 63: 3112-20.
44. Rutz HP, Mariotta M, von Knebel Doeberitz M, Mirimanoff RO. Dexamethasone-induced radioresistance occurring independent ofhuman papilloma virus gene expression in cervical carcinoma cells. Strahlenther Onkol 1998; 174: 71-4.
45. Kamradt MC, Walter S, Koudelik J, et al. Steroid-mediated inhibi-tion of radiation-induced apoptosis in C4-1 cervical carcinoma cellsis p53-dependent. Eur J Cancer 2001; 37: 2240-6.
46. Kamradt MC, Mohideen N, Krueger E, Walter S, Vaughan AT. Inhibition of radiation-induced apoptosis by dexamethasone in cer-vical carcinoma cell lines depends upon increased HPV E6/E7. Br JCancer 2000; 82: 1709-16.
47. Zhang C, Kolb A, Mattern J, et al. Dexamethasone desensitizeshepatocellular and colorectal tumours toward cytotoxic therapy. Cancer Lett 2006; 242: 104-11.
48. Evans-Storms RB, Cidlowski JA. Delineation of an antiapoptoticaction of glucocorticoids in hepatoma cells: the role of nuclear fac-tor-kappaB. Endocrinology 2000; 141: 1854-62.
49. Bergman AM, Pinedo HM, Peters GJ. Steroids affect collateralsensitivity to gemcitabine of multidrug-resistant human lung cancercells. Eur J Pharmacol 2001; 416 19-24.
50. Wen LP, Madani K, Fahrni JA, Duncan SR, Rosen GD. Dex-amethasone inhibits lung epithelial cell apoptosis induced by IFN-gamma and Fas. Am J Physiol 1997; 273: L921-9.
51. Gassler N, Zhang C, Wenger T, et al. Dexamethasone-inducedcisplatin and gemcitabine resistance in lung carcinoma samplestreated ex vivo. Br J Cancer 2005; 92: 1084-8.
52. Zhang C, Marme A, Wenger T, et al. Glucocorticoid-mediatedinhibition of chemotherapy in ovarian carcinomas. Int J Oncol 2006; 28: 551-8.
53. Feng Z, Marti A, Jehn B, et al. Glucocorticoid and progesteroneinhibit involution and programmed cell death in the mouse mam-mary gland. J Cell Biol 1995; 131: 1095-103.
54. Lund LR, Romer J, Thomasset N, et al. Two distinct phases ofapoptosis in mammary gland involution: proteinase-independentand -dependent pathways. Development 1996; 122: 181-93.
55. Murtagh J, McArdle E, Gilligan E, et al. Organization of mammaryepithelial cells into 3D acinar structures requires glucocorticoid andJNK signaling. J Cell Biol 2004; 166: 133-43.
56. Sumikawa T, Shigeoka Y, Igishi T, et al. Dexamethasone interfereswith trastuzumab-induced cell growth inhibition through restora-tion of AKT activity in BT-474 breast cancer cells. Int J Oncol 2008; 32: 683-8.
57. Kim MJ, Chae JS, Kim KJ, et al. Negative regulation of SEK1signaling by serum- and glucocorticoid-inducible protein kinase 1. EMBO J 2007; 26: 3075-85.
58. Moran TJ, Gray S, Mikosz CA, Conzen SD. The glucocorticoidreceptor mediates a survival signal in human mammary epithelialcells. Cancer Res 2000; 60: 867-72.
59. Huang Y, Johnson KR, Norris JS, Fan W. Nuclear factor-kappaB/IkappaB signaling pathway may contribute to the media-tion of paclitaxel-induced apoptosis in solid tumor cells. CancerRes 2000; 60: 4426-32.
60. Pew T, Zou M, Brickley DR, Conzen SD. Glucocorticoid (GC)-mediated down-regulation of urokinase plasminogen activator ex-pression via the serum and GC regulated kinase-1/forkhead boxO3a pathway. Endocrinology 2008; 149: 2637-45.
61. Machuca C, Mendoza-Milla C, Cordova E, et al. Dexamethasoneprotection from TNF-alpha-induced cell death in MCF-7 cells re-quires NF-kappaB and is independent from AKT. BMC Cell Biol 2006; 7: 9.
62. Sahoo S, Brickley DR, Kocherginsky M, Conzen SD. Coordinateexpression of the PI3-kinase downstream effectors serum and glu-cocorticoid-induced kinase (SGK-1) and Akt-1 in human breastcancer. Eur J Cancer 2005; 41: 2754-9.
63. Elahian F, Kalalinia F, Behravan J. Evaluation of indomethacin anddexamethasone effects on BCRP-mediated drug resistance in MCF-7 parental and resistant cell lines. Drug Chem Toxicol 2010; 33:113-9.
64. Elahian F, Kalalinia F, Behravan J. Dexamethasone downregulatesBCRP mRNA and protein expression in breast cancer cell lines. Oncol Res 2009; 18: 9-15.
65. Wang H, Wang Y, Rayburn ER, et al. Dexamethasone as a che-mosensitizer for breast cancer chemotherapy: potentiation of theantitumor activity of adriamycin, modulation of cytokine expres-sion, and pharmacokinetics. Int J Oncol 2007; 30: 947-53.
66. Eismann EA, Lush E, Sephton SE. Circadian effects in cancer-relevant psychoneuroendocrine and immune pathways. Psychoneu-roendocrinology 2010; 35(7): 963-76.
67. Granda TG, Filipski E, D'Attino RM, et al. Experimental chrono-therapy of mouse mammary adenocarcinoma MA13/C with do-cetaxel and doxorubicin as single agents and in combination. Can-cer Res 2001; 61: 1996-2001.
68. Chen ST, Choo KB, Hou MF, et al. Deregulated expression of thePER1, PER2 and PER3 genes in breast cancers. Carcinogenesis 2005; 26: 1241-6.
69. Hrushesky WJ, Grutsch J, Wood P, et al. Circadian clock manipu-lation for cancer prevention and control and the relief of cancersymptoms. Integr Cancer Ther 2009; 8: 387-97.
70. Hrushesky WJ, Lannin D, Haus E. Evidence for an ontogeneticbasis for circadian coordination of cancer cell proliferation. J NatlCancer Inst 1998; 90: 1480-4.
71. Abrahamsen JF, Smaaland R, Sandberg S, Aakvaag A, Lote K.Circadian variation in serum cortisol and circulating neutrophils aremarkers for circadian variation of bone marrow proliferation incancer patients. Eur J Haematol 1993; 50 206-12.
72. Vaidya JS, Joseph DJ, Tobias JS, et al. Targeted intraoperativeradiotherapy versus whole breast radiotherapy for breast cancer(TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet 2010; 376: 91-102.
73. Vaidya JS, Baum M, Tobias JS, et al. Long term results of Tar-geted Intraoperative Radiotherapy (Targit) Boost During BreastConserving Surgery. Int J Radiat Oncol Biol Phys 2010; published online doi:10.1016/j.ijrobp.2010.07.1996.
74. Vaidya JS, Baum M, Tobias JS, et al. Targeted intra-operativeradiotherapy (Targit): an innovative method of treatment for earlybreast cancer. Ann Oncol 2001; 12: 1075-80.
75. Vaidya JS, Baum M, Tobias JS, Morgan S, D'Souza D. The noveltechnique of delivering targeted intraoperative radiotherapy (Tar-git) for early breast cancer. Eur J Surg Oncol 2002; 28: 447-54.
76. Vaidya JS. A novel approach for local treatment of early breastcancer. PhD Thesis. University of London 2002;http://www.ucl.ac.uk/~rmhkjsv/papers/thesis.htm.
77. Smith RA, Lea RA, Curran JE, Weinstein SR, Griffiths LR. Ex-pression of glucocorticoid and progesterone nuclear receptor genesin archival breast cancer tissue. Breast Cancer Res 2003; 5: R9-12.
78. Smith RA, Lea RA, Weinstein SR, Griffiths LR. Progesterone,glucocorticoid, but not estrogen receptor mRNA is altered in breastcancer stroma. Cancer Lett 2007; 255: 77-84.
79. Buxant F, Engohan-Aloghe C, Noel JC. Estrogen receptor, proges-terone receptor, and glucocorticoid receptor expression in normalbreast tissue, breast in situ carcinoma, and invasive breast cancer.Appl Immunohistochem Mol Morphol 2010; 18: 254-7.
80. Conde I, Paniagua R, Fraile B, Lucio J, Arenas MI. Glucocorticoidreceptor changes its cellular location with breast cancer develop-ment. Histol Histopathol 2008; 23: 77-85.
81. Belova L, Delgado B, Kocherginsky M, et al. Glucocorticoid re-ceptor expression in breast cancer associates with older patient age. Breast Cancer Res Treat 2009; 116: 441-7.
82. Keith BD. Systematic review of the clinical effect of glucocorti-coids on nonhematologic malignancy. BMC Cancer 2008; 8: 84.
83. Colsky J. A comparative study of 9alpha-bromo-11beta-keto-progesterone and prednisolone in the treatment of advanced carci-noma of the female breast. Cancer 1963; 16: 502-5.
84. Goldenberg I. Clinical trial of delta-1-testololactone (NSC 23759),medroxy progesterone acetate (NSC 26386) and oxylone acetate(NSC 47438) in advanced female mammary cancer. A report of thecooperative breast cancer group. Cancer 1969; 23: 109-12.
85. Gaertner R, Lewison E, Finney G, Montague A. Combined hor-mone therapy in advanced breast cancer. Triple-blind study of 68patients treated with dromostanolone and fluorometholone. JohnsHopkins Med J 1968; 123: 138-41.
86. Dao T, Tan E, Brooks V. A comparative evaluation of adrenalec-tomy and cortisone in the treatment of advanced mammary carci-noma. Cancer 1961; 14: 1259-65.
87. Talley R, Brennan M, Vaitkevicius V, et al. Comparison of 6-alpha-methyl-9-alpha-fluoro-17-acetoxy-21-deoxyprednisolonewith fluoxymesterone and methylprednisolone in treatment of me-tastatic breast cancer. Cancer 1964; 17: 1063-6.
88. Jakobsen A, Frederiksen P, Moller K, et al. Medroxyprogesteroneacetate and prednisone in advanced breast cancer. A randomizedtrial. Eur J Cancer Clin Oncol 1986; 22: 1067-72.
89. Kristensen B, Ejlertsen B, Holmegaard S, et al. Prednisolone in thetreatment of severe malignant hypercalcaemia in metastatic breastcancer: a randomized study. J Intern Med 1992; 232: 237-45.
90. Mercer P, Ebbs S, Fraser S, Coltart R, Bates T. Trial of aminoglu-tethimide vs hydrocortisone as second-line hormone treatment ofadvanced breast cancer 1997; US-FDA document at http://www.fda.gov/ohrms/dockets/ac/97/transcpt/3289t2.pdf ac-cessed on 10/07/2010.
91. Wander H, Kleeberg U, Essers U, Blossey H, Nagel G. Aminoglu-tethimide plus high-dose medroxyprogesterone acetate versus ami-noglutethimide plus cortisone in therapy of metastasizing breastcancer. An AIO phase III study. Onkologie 1987; 10: 321-3.
92. Ingle J, Mailliard J, Schaid D, et al. A double-blind trial of ta-moxifen plus prednisolone versus tamoxifen plus placebo in post-menopausal women with metastatic breast cancer. A collaborativetrial of the North Central Cancer Treatment Group and MayoClinic. Cancer 1991; 68: 34-9.
93. Stewart J, Rubens R, King R, et al. Contribution of prednisolone tothe primary endocrine treatment of advanced breast cancer. Eur JCancer Clin Oncol 1982; 18: 1307-14.
94. Cocconi G, Bisagni G, Ceci G, et al. Low-dose aminoglutethimidewith and without hydrocortisone replacement as a first-line endo-crine treatment in advanced breast cancer: a prospective random-ized trial of the Italian Oncology Group for Clinical Research. JClin Oncol 1992; 10: 984-9.
95. Rubens R, Tinson C, Coleman R, et al. Prednisolone improves theresponse to primary endocrine treatment for advanced breast can-cer. Br J Cancer 1988; 58: 626-30.
96. Ramirez G, Klotz J, Strawitz J, et al. Combination chemotherapy inbreast cancer: a randomized study of 4 versus 5 drugs. Oncology 1975; 32: 101-8.
97. Brambilla C, De Lena M, Bonadonna G. Combination chemother-apy with adriamycin (NSC-123127) in metastatic mammary carci-noma. Cancer Chemother Rep 1974; 58: 251-3.
98. Tormey D, Gelman R, Band P, et al. Comparison of inductionchemotherapies for metastatic breast cancer. An Eastern Coopera-tive Oncology Group Trial. Cancer 1982; 50: 1235-44.
99. Rossi A, Brambilla C, Bonadonna G. Controlled study with 1-phenylalanine mustard (l-PAM) and 5-fluorouracil (5-FU) plus orminus prednisone in advanced breast cancer. Tumori 1976; 62:193-6.
100. Piccart M, Klijn J, Paridaens R, et al. Corticosteroids significantlydelay the onset of docetaxel-induced fluid retention: final results ofa randomized study of the European Organization for Research andTreatment of Cancer Investigational Drug Branch for Breast Can-cer. J Clin Oncol 1997; 15: 3149-55.
101. Gercovich F, Negro A, Requejo H, et al. 5Fluorouracil, cyclophos-phamide and mitoxantrone (fucimix) vs fucimix-prednisone (pdn)for advanced breast cancer (abc). A prospective and randomizedtrial. Preliminar report. Proc AACR 1989; 30: 1014.
102. Tashiro H, Nomura Y. Mitomycin C methotrexate, and vincristine with medroxyprogesterone acetate or prednisolone for doxorubicinresistant advanced breast cancer--a randomized control study. Anti-cancer Res 1995; 15: 2229-37.
103. Tormey D, Gelman R, Falkson G. Prospective evaluation of rotat-ing chemotherapy in advanced breast cancer. An Eastern Coopera-tive Oncology Group Trial. Am J Clin Oncol 1983; 6: 1-18.
104. Redondo M, Tellez T, Roldan MJ, et al. Anticlusterin treatment ofbreast cancer cells increases the sensitivities of chemotherapy andtamoxifen and counteracts the inhibitory action of dexamethasoneon chemotherapy-induced cytotoxicity. Breast Cancer Res 2007; 9:R86.
105. Fentiman I, Howell A, Hamed H, et al. A controlled trial of adju-vant tamoxifen, with or without prednisolone, in post-menopausalwomen with operable breast cancer. Br J Cancer 1994; 70: 729-31.
106. DiMartino L, Demontis B, Mitchell I, Hayward S, Deshpande N. Arandomized clinical trial to investigate the usefulness of the addi-tion of prednisolone to tamoxifen as adjuvants to mastectomy inprimary breast cancer patients with a high risk of recurrence: a pre-liminary report. Anticancer Res 1991; 11: 869-72.
107. Meakin J, Hayward J, Panzarella T, et al. Ovarian irradiation andprednisone following surgery and radiotherapy for carcinoma of thebreast. Breast Cancer Res Treat 1996; 37: 11-9.
108. Lundholm K, Gelin J, Hyltander A, et al. Adjuvant ovarian ablationversus CMF chemotherapy in premenopausal women with patho-logical stage II breast carcinoma: the Scottish trial. Scottish CancerTrials Breast Group and ICRF Breast Unit, Guy's Hospital, LondonAnti-inflammatory treatment may prolong survival in undernour-ished patients with metastatic solid tumors. Lancet 1993; 341:1293-8.
109. McCloskey EV, Hannon RA, Lakner G, et al. Effects of third gen-eration aromatase inhibitors on bone health and other safety pa-rameters: results of an open, randomised, multi-centre study of le-trozole, exemestane and anastrozole in healthy postmenopausalwomen. Eur J Cancer 2007; 43: 2523-2531.
110. Lonning PE. The potency and clinical efficacy of aromatase inhibi-tors across the breast cancer continuum. Ann Oncol 2010; In press: [Epub ahead of print], DOI: 10.1093/annonc/mdq337.
111. Tormey D, Gray R, Gilchrist K, et al. Adjuvant chemohormonaltherapy with cyclophosphamide, methotrexate, 5-fluorouracil, andprednisone (CMFP) or CMFP plus tamoxifen compared with CMFfor premenopausal breast cancer patients. An Eastern CooperativeOncology Group trial. Cancer 1990; 65: 200-206.
112. Marini G, Murray S, Goldhirsch A, et al. The effect of adjuvantprednisone combined with CMF on patterns of relapse and occur-rence of second malignancies in patients with breast cancer. Inter-national (Ludwig) Breast Cancer Study Group. Ann Oncol 1996; 7:245-250.
113. Kemeny N, Conti J, Cohen A, et al. A randomized trial of adjuvantcombination chemotherapy with or without prednisone inpremenopausal breast cancer patients with metastases in one tothree axillary lymph nodes. Ludwig Breast Cancer Study GroupPhase II study of hepatic arterial floxuridine, leucovorin, and dex-amethasone for unresectable liver metastases from colorectal carci-noma. Cancer Res 1985; 45: 4454-4459.
114. Coimbra M, Kuijpers SA, van Seters SP, Storm G, Schiffelers RM.Targeted delivery of anti-inflammatory agents to tumors. CurrPharm Des 2009; 15(16): 1825-1843.
115. Sisci D, Surmacz E. Crosstalk between IGF signaling and steroidhormone receptors in breast cancer. Curr Pharm Des 2007; 13(7):705-717.
116. Murakami M, Kudo I. Prostaglandin E synthase: a novel drug tar-get for inflammation and cancer. Curr Pharm Des 2006; 12(8): 943-954.